Compounds and methods for treatment and prevention of diseases

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C540S456000

Reexamination Certificate

active

07960405

ABSTRACT:
A prodrug compound of a rapamycin analog and methods for inhibiting, treating, and preventing mammalian diseases.

REFERENCES:
patent: 4580568 (1986-04-01), Gianturco
patent: 4733665 (1988-03-01), Palmaz
patent: 4916193 (1990-04-01), Tang et al.
patent: 4994071 (1991-02-01), MacGregor
patent: 5092877 (1992-03-01), Pinchuk
patent: 5163952 (1992-11-01), Froix
patent: 5260300 (1993-11-01), Hu
patent: 5304121 (1994-04-01), Sahatjian
patent: 5346893 (1994-09-01), Failli et al.
patent: 5355832 (1994-10-01), Loh et al.
patent: 5380299 (1995-01-01), Fearnot et al.
patent: 5447724 (1995-09-01), Helmus et al.
patent: 5447799 (1995-09-01), Loh et al.
patent: 5464650 (1995-11-01), Berg et al.
patent: 5527907 (1996-06-01), Or et al.
patent: 5583139 (1996-12-01), Or et al.
patent: 5605696 (1997-02-01), Eury et al.
patent: 5624411 (1997-04-01), Tuch
patent: 5672605 (1997-09-01), Or et al.
patent: 5705583 (1998-01-01), Bowers et al.
patent: 5755771 (1998-05-01), Penn et al.
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5873904 (1999-02-01), Ragheb et al.
patent: 6015815 (2000-01-01), Mollison
patent: 6033434 (2000-03-01), Borghi
patent: 6083257 (2000-07-01), Taylor et al.
patent: 6090901 (2000-07-01), Bowers et al.
patent: 6106548 (2000-08-01), Roubin et al.
patent: 6248129 (2001-06-01), Froix
patent: 6273913 (2001-08-01), Wright et al.
patent: 6284305 (2001-09-01), Ding et al.
patent: 6299604 (2001-10-01), Ragheb et al.
patent: 6329386 (2001-12-01), Mollison
patent: 6358556 (2002-03-01), Ding et al.
patent: 6419692 (2002-07-01), Yang et al.
patent: 6585764 (2003-07-01), Wright et al.
patent: 2001/0029351 (2001-10-01), Falotico et al.
patent: 2002/0123505 (2002-09-01), Mollison et al.
patent: 2002/0127263 (2002-09-01), Carlyle et al.
patent: 1 236 478 (2002-02-01), None
patent: WO 94/15583 (1994-07-01), None
patent: WO 99/15530 (1999-04-01), None
patent: WO 01/87372 (2001-11-01), None
patent: WO 02/26281 (2002-04-01), None
patent: WO 02/055122 (2002-07-01), None
patent: WO 02/066092 (2002-08-01), None
Alt et al., “Inhibition of Neointima Formation After Experimental Coronary Artery Stenting; A New Biodegradable Stent Coating Releasing Hirudin and the Prostacyclin Analogue Iloprost”, Circulation, pp. 1453-1458 (2000).
Burke et al., “Neointimal Formation After Ballon-Induced Vascular Injury in Yucatan Minipigs is Reduced by Oral Rapamycin”, Journal for Cardiovascular Pharmacology vol. 33, pp. 829-835 (1999).
Gallo, MD, et al., “Inhibition of Intimal Thickening After Ballon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle”, Circulation, pp. 2164-2170 (1999).
Michael Poon et al., “Rapamycin Inhibits Vascular Smooth Muscle Cell Migration”, Journal of Clinical Investigation, vol. 98, No. 10, pp. 2277-2283 (1996).
Sousa et al., “Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries”, Circulation, pp. 192-194 (2001).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compounds and methods for treatment and prevention of diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and methods for treatment and prevention of diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treatment and prevention of diseases will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2741608

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.